Clusterin for use in the treatment of thrombotic microangiopathies
US12186366B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 20, 2018 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Oct 28, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/226
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC/Lref, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.